Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recordati Industria Chimica & Farmaceutica SPA

www.recordati.com

Latest From Recordati Industria Chimica & Farmaceutica SPA

Recordati’s OTC Sales Lifted by Acquisitions And Italy

Italy's Recordati enjoyed strong growth in its home market and abroad, lifting OTC group sales in 2019.

Sales & Earnings Italy

EMA Reviewing Two Centralised Switch Applications

Teva's Ratiopharm and Italy's Recordati have submitted applications to switch drugs from prescription-to-OTC status through EMA's centralised procedure. Given only four products have been switched centrally to date, a double reclassification would be unprecedented. 

Prescription To Otc Switch Europe

Keeping Track: US FDA Clears Sanofi’s Sarclisa; KemPharm Submits Novel ADHD Drug

The latest drug development news and highlights from the Pink Sheet FDA Performance Tracker.

US FDA Performance Tracker Approvals

Alnylam Pursues Value Framework To Accelerate Givlaari Access In EU

Alnylam’s short-interfering RNA, Givlaari, has become the first treatment to be approved for preventing attacks of acute hepatic porphyria in the EU, and Alnylam wants to pursue a value-based agreement framework to accelerate patient and provider access.

Rare Diseases Approvals
See All

Company Information

UsernamePublicRestriction

Register